Stock listing
gettex:5VB Nykode Therapeutics ASA Aktie
German listing (gettex) of Nykode Therapeutics ASA · home listing Oslo:NYKD
Follow Nykode Therapeutics ASA into a list and get an email when it puts out news.
Home listing price · OSL:NYKD
2.67 NOK -0.08 (-2.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OSL:NYKD
- Day range
- 2.62 – 2.76 NOKNov 20, 2026
- Volume
- 1.15M sharesNov 20, 2026
- Market cap
- 1.04B NOKAt the close on Nov 20, 2026 · price × 391.5M shares outstanding
- 52-week range
- 2.06 – 5.20 NOKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 7.67M NOKMedian day 1.04M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Oslo:NYKD · Home | 2.665 NOK | -0.075 (-2.7%) | 1,153,599 | 2.75 | 2.755 | 2.62 | 2.74 | Close on Nov 20, 2026 |
| OTC:VACBF | $0.297 USD | 0.000 (0.0%) | — | $0.297 | $0.297 | $0.297 | $0.297 | Close on Nov 6, 2026 |
| Stuttgart:5VB | €0.233 EUR | -0.007 (-2.9%) | — | €0.238 | €0.247 | €0.215 | €0.240 | Close on Nov 20, 2026 |
| Frankfurt:5VB | €0.211 EUR | -0.009 (-3.9%) | — | €0.211 | €0.211 | €0.211 | €0.219 | Close on Nov 20, 2026 |
| Munich:5VB | €0.322 EUR | -0.002 (-0.5%) | — | €0.322 | €0.322 | €0.322 | €0.323 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OSL:NYKD · NOK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.665 | -0.075 | -2.7% | 2.75 | 2.755 | 2.62 | 1,153,599 | |
| 2.74 | 0.00 | 0.0% | 2.80 | 2.815 | 2.74 | 574,244 | |
| 2.74 | -0.075 | -2.7% | 2.81 | 2.825 | 2.74 | 806,252 | |
| 2.815 | -0.05 | -1.7% | 2.88 | 2.885 | 2.815 | 344,412 | |
| 2.865 | -0.025 | -0.9% | 2.89 | 2.95 | 2.865 | 439,366 | |
| 2.89 | -0.07 | -2.4% | 3.00 | 3.00 | 2.89 | 466,321 | |
| 2.96 | +0.03 | +1.0% | 2.985 | 3.025 | 2.96 | 577,247 | |
| 2.93 | -0.045 | -1.5% | 2.95 | 3.00 | 2.89 | 1,565,169 | |
| 2.975 | -0.015 | -0.5% | 3.15 | 3.15 | 2.975 | 444,557 | |
| 2.99 | +0.03 | +1.0% | 2.95 | 3.04 | 2.92 | 684,650 | |
| 2.96 | -0.115 | -3.7% | 3.16 | 3.20 | 2.96 | 847,907 | |
| 3.075 | +0.085 | +2.8% | 2.945 | 3.20 | 2.945 | 672,888 | |
| 2.99 | +0.08 | +2.7% | 2.905 | 3.015 | 2.80 | 811,582 | |
| 2.91 | -0.095 | -3.2% | 2.985 | 3.02 | 2.91 | 649,707 | |
| 3.005 | -0.015 | -0.5% | 3.00 | 3.075 | 2.945 | 1,173,671 | |
| 3.02 | -0.04 | -1.3% | 3.08 | 3.08 | 3.015 | 755,085 | |
| 3.06 | -0.07 | -2.2% | 3.145 | 3.145 | 3.02 | 1,550,380 | |
| 3.13 | 0.00 | 0.0% | 3.15 | 3.15 | 3.10 | 388,339 | |
| 3.13 | -0.02 | -0.6% | 3.16 | 3.19 | 3.10 | 343,539 | |
| 3.15 | -0.065 | -2.0% | 3.125 | 3.21 | 3.12 | 863,731 | |
| 3.215 | -0.105 | -3.2% | 3.28 | 3.345 | 3.175 | 769,630 | |
| 3.32 | +0.14 | +4.4% | 3.18 | 3.35 | 3.18 | 1,089,822 | |
| 3.18 | -0.01 | -0.3% | 3.245 | 3.245 | 3.11 | 361,457 | |
| 3.19 | +0.065 | +2.1% | 3.13 | 3.20 | 3.10 | 1,277,181 | |
| 3.125 | 0.00 | 0.0% | 3.125 | 3.175 | 3.125 | 288,242 | |
| 3.125 | -0.055 | -1.7% | 3.335 | 3.335 | 3.10 | 421,455 | |
| 3.18 | -0.025 | -0.8% | 3.23 | 3.23 | 3.135 | 1,715,845 | |
| 3.205 | -0.21 | -6.1% | 3.305 | 3.425 | 3.015 | 3,813,154 | |
| 3.415 | -0.025 | -0.7% | 3.495 | 3.495 | 3.38 | 471,223 | |
| 3.44 | +0.04 | +1.2% | 3.38 | 3.52 | 3.38 | 622,472 | |
| 3.40 | -0.125 | -3.5% | 3.525 | 3.525 | 3.38 | 1,096,763 | |
| 3.525 | -0.03 | -0.8% | 3.52 | 3.565 | 3.47 | 499,985 | |
| 3.555 | -0.04 | -1.1% | 3.61 | 3.64 | 3.555 | 417,038 | |
| 3.595 | +0.12 | +3.5% | 3.455 | 3.595 | 3.455 | 494,432 | |
| 3.475 | +0.025 | +0.7% | 3.50 | 3.50 | 3.45 | 407,047 | |
| 3.45 | -0.12 | -3.4% | 3.69 | 3.69 | 3.41 | 1,456,871 | |
| 3.57 | -0.02 | -0.6% | 3.585 | 3.645 | 3.555 | 893,560 | |
| 3.59 | -0.02 | -0.6% | 3.63 | 3.725 | 3.58 | 881,341 | |
| 3.61 | -0.295 | -7.6% | 3.55 | 3.675 | 3.50 | 3,322,565 | |
| 3.905 | +0.09 | +2.4% | 3.81 | 3.95 | 3.80 | 1,455,737 | |
| 3.815 | -0.12 | -3.0% | 3.935 | 3.955 | 3.815 | 1,436,951 | |
| 3.935 | -0.095 | -2.4% | 4.02 | 4.065 | 3.935 | 629,340 | |
| 4.03 | +0.06 | +1.5% | 4.00 | 4.105 | 3.985 | 896,598 | |
| 3.97 | -0.08 | -2.0% | 4.18 | 4.18 | 3.955 | 1,206,542 | |
| 4.05 | +0.03 | +0.7% | 4.01 | 4.195 | 4.00 | 2,143,022 | |
| 4.02 | +0.095 | +2.4% | 3.91 | 4.03 | 3.905 | 761,275 | |
| 3.925 | +0.115 | +3.0% | 3.875 | 3.95 | 3.785 | 977,792 | |
| 3.81 | -0.05 | -1.3% | 3.80 | 3.86 | 3.765 | 1,221,177 | |
| 3.86 | -0.09 | -2.3% | 3.92 | 3.94 | 3.855 | 1,288,557 | |
| 3.95 | -0.09 | -2.2% | 4.09 | 4.10 | 3.95 | 1,994,420 | |
| 4.04 | -0.16 | -3.8% | 4.14 | 4.21 | 4.02 | 1,769,194 | |
| 4.20 | +0.20 | +5.0% | 3.99 | 4.215 | 3.93 | 1,834,055 | |
| 4.00 | -0.025 | -0.6% | 4.05 | 4.125 | 3.99 | 1,713,271 | |
| 4.025 | -0.07 | -1.7% | 4.05 | 4.13 | 3.985 | 1,336,844 | |
| 4.095 | +0.015 | +0.4% | 4.14 | 4.14 | 4.05 | 997,829 | |
| 4.08 | -0.03 | -0.7% | 4.175 | 4.20 | 4.055 | 1,845,455 | |
| 4.11 | +0.035 | +0.9% | 4.115 | 4.285 | 4.085 | 4,187,115 | |
| 4.075 | -0.215 | -5.0% | 4.28 | 4.28 | 3.99 | 5,223,055 | |
| 4.29 | -0.01 | -0.2% | 4.275 | 4.37 | 4.10 | 4,990,942 | |
| 4.30 | -0.69 | -13.8% | 4.56 | 4.665 | 4.255 | 12,405,180 | |
| 4.99 | +0.39 | +8.5% | 4.995 | 5.05 | 4.72 | 4,663,385 | |
| 4.60 | -0.04 | -0.9% | 4.78 | 5.20 | 4.10 | 11,640,937 | |
| 4.64 | +0.08 | +1.8% | 4.605 | 4.75 | 4.485 | 1,905,918 | |
| 4.56 | +0.05 | +1.1% | 4.59 | 4.70 | 4.36 | 3,036,452 | |
| 4.51 | +0.41 | +10.0% | 4.195 | 4.715 | 4.12 | 6,809,048 | |
| 4.10 | -0.83 | -16.8% | 5.10 | 5.17 | 4.10 | 13,655,594 |
- Ticker
- gettex:5VB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Aug 20, 2026
Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program
Latest earnings call · Aug 26, 2026
Nykode Therapeutics (Oslo:NYKD) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Sep 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference 2026
Conference · 27 slides
Latest news
Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program
Aug 20, 2026
Closed 4.10 (-16.8%) on Aug 20, 2026
Q1 2026 Financial Results Q1 2026 Webcast presentation
May 27, 2026
Closed 3.15 (-6.4%) on May 27, 2026
Q1 2026 Financial Results Nykode Q1 2026 Report
May 27, 2026
Closed 3.15 (-6.4%) on May 27, 2026
Nykode Therapeutics reports Q1 2026 Financial Results
May 27, 2026
Closed 3.15 (-6.4%) on May 27, 2026
Nykode Therapeutics - Quarterly Report Q1 2026
May 27, 2026
Closed 3.15 (-6.4%) on May 27, 2026
Invitation to Q1 2026 Financial Results Presentation
May 18, 2026
Closed 3.17 (+2.4%) on May 18, 2026
Q4 2025 Financial Results Q4 2025 Webcast presentation
Feb 27, 2026
Closed 2.89 (-8.5%) on Feb 27, 2026
Nykode Therapeutics reports Q4 2025 Financial Results
Feb 25, 2026
Closed 3.26 (-9.7%) on Feb 25, 2026
Q4 2025 Financial Results Nykode Q4 2025 Report
Feb 25, 2026
Closed 3.26 (-9.7%) on Feb 25, 2026
Nykode Therapeutics - Quarterly Report Q4 2025
Feb 25, 2026
Closed 3.26 (-9.7%) on Feb 25, 2026
Nykode Therapeutics ASA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 12 in all · newest Aug 20, 2026 · oldest 2026
- Calls
- 11 calls with a replay · 11 with a transcript · latest Aug 26, 2026
- Decks
- 54 decks · latest Sep 16, 2026
Where Nykode Therapeutics ASA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Oslo:NYKD · Home listing | Oslo | Norway | NOK |
| Aquis:NYKDO | Aquis | United Kingdom | NOK |
| OTC:VACBF | OTC | United States | USD |
| gettex:5VB · This page | gettex | Germany | EUR |
| Stockholm:NYKDO | Stockholm | Sweden | NOK |
| Lang & Schwarz:A2PZ5J | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PZ5J | LS Exchange | Germany | EUR |
| Stuttgart:5VB | Stuttgart | Germany | EUR |
| Turquoise:NYKDO | Turquoise | United Kingdom | NOK |
| Aquis:NYKDO | Aquis | United Kingdom | NOK |
| Dusseldorf:5VB | Dusseldorf | Germany | EUR |
| Frankfurt:5VB | Frankfurt | Germany | EUR |
| Munich:5VB | Munich | Germany | EUR |
Valuation
Price/book 1.3× against a median of 3.0×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 606.8M NOK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| Spruce Biosciences, Inc. · NASDAQ:SPRB | US$109.2M | US$41.00M | n/a | n/a | n/a | 1.6× | n/a | 0.3× | 1.73 |
| NIBEC Co., Ltd. · KRX:138610 | US$108.7M | US$92.50M | n/a | 5.5× | 118× | 3.0× | −0.1% | 0.0× | n/a |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Median of the others | US$104.8M | US$83.89M | 10.9× | 5.5× | 57.5× | 3.0× | −97.9% | 0.0× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 NOK · Analysts' mean
- EPS, year to Dec 2026
- -0.75 · 2 analysts
- Revenue, year to Dec 2026
- 928K · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Engsig | Chief Executive Officer |
| Harald Gurvin | Chief Financial Officer |
| Louise Stubbe | Chief Legal Officer |
| Agnete B. Fredriksen | Chief Scientific Officer & Business Development |
| Jakob Helding Rasmussen | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Barbara Krebs-Pohl | Chair of the Board |
| Christian Åbyholm | Board Member |
| John Beadle | Board Member |
| Susanne Stuffers | Board Member |
| Trygve Lauvdal | Board Member |
Events
- Next results
- Nov 23, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Nykode Therapeutics (Oslo:NYKD) Q2 2026 Earnings Call | Wed, Aug 26, 2026 · 3:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q1 2026 Earnings Call | Wed, May 27, 2026 · 9:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 7:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q3 2025 Earnings Call | Mon, Nov 24, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q2 2025 Earnings Call | Wed, Aug 27, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q1 2025 Earnings Call | Wed, May 28, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 7:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q3 2024 Earnings Call | Wed, Nov 27, 2024 · 2:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q2 2024 Earnings Call | Wed, Aug 21, 2024 · 2:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2022 Earnings Call | Tue, Feb 28, 2023 · 10:00 AM ET | Replay |
All 11 calls
| Call | When | Status |
|---|---|---|
| Nykode Therapeutics (Oslo:NYKD) Q3 2022 Earnings Call | Wed, Nov 23, 2022 · 9:58 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 26, 2026 · Before open | −0.9% |
| Q1 2026 | May 27, 2026 · Before open | −6.4% |
| Q4 2025 | Feb 25, 2026 · Before open | −9.7% |
| Q3 2025 | Nov 23, 2025 · After close | +3.6% |
| Q2 2025 | Aug 27, 2025 · Before open | −9.8% |
| Q1 2025 | May 27, 2025 · After close | −1.1% |
| Q4 2024 | Feb 26, 2025 · Before open | +1.4% |
| Q3 2024 | Nov 26, 2024 · After close | +5.0% |
| Q2 2024 | Aug 21, 2024 · Before open | −47.0% |
| Q1 2024 | May 14, 2024 · Before open | +2.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 28, 2024 · Before open | −5.8% |
| Q3 2023 | Nov 15, 2023 · After close | +1.1% |
| Q2 2023 | Aug 22, 2023 · After close | −0.2% |
| Q1 2023 | May 12, 2023 · Before open | +5.7% |
| Q4 2022 | Feb 28, 2023 · Before open | −2.5% |
| Q3 2022 | Nov 23, 2022 · Before open | −1.8% |
| Q2 2022 | Aug 24, 2022 · Before open | +0.5% |
| Q1 2022 | May 16, 2022 · Before open | −4.4% |
| Q3 2021 | Nov 17, 2021 · Before open | −0.9% |
| Quarter to Jun 30, 2021 | Aug 26, 2021 · Before open | −4.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H.C. Wainwright 28th Annual Global Investment Conference 2026 | Conference | 27 slides | Sep 16, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 28 slides | Aug 26, 2026 |
| Investor Presentation (August 2026) | Investor deck | 73 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 27 slides | May 27, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 67 slides | May 27, 2026 |
| DNB Carnegie's Nordic Healthcare Conference 2026 | Conference | 32 slides | Mar 10, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 31 slides | Feb 25, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 93 slides | January 2026 |
| Investor Presentation (December 2025) | Investor deck | 93 slides | December 2025 |
All 54 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 8.68M | 12.9M | 7.17M | 34.0M | 215.0M | 12.4M | 12.0M | 9.76M | 24.0K |
| Gross profit | 8.68M | 12.9M | 7.17M | 34.0M | 215.0M | 12.4M | 12.0M | 9.76M | ||
| Research and development | 13.4M | 14.7M | 29.4M | 26.8M | 16.3M | 10.6M | 60.8M | |||
| Selling, general and administrative | 13.6M | 4.34M | 6.28M | 8.89M | 9.28M | 8.56M | 6.08M | 2.32M | 1.60M | 841.5K |
| Operating income | -28.6M | -48.3M | -58.1M | -53.2M | -10.8M | 178.3M | -122.4M | -65.8M | -34.0M | -1.62M |
| Depreciation and amortization | 2.04M | 743.0K | 629.0K | 1.81M | 734.0K | 304.0K | 1.40M | 58.0K | 58.0K | 8.31K |
| EBITDA | -26.5M | -47.6M | -57.5M | -51.3M | -10.0M | 178.6M | -121.0M | -65.8M | -33.9M | -1.61M |
| Interest expense | 125.0K | 6.18M | 4.68M | 241.0K | 130.0K | 46.0K | 24.0K | 9.20K | 0 | 0 |
| Income before tax | -17.7M | -45.5M | -44.1M | -51.0M | -11.1M | 180.9M | -120.2M | -63.8M | -31.4M | -1.60M |
| Income tax | -6.69M | -8.93M | -8.24M | -1.70M | 31.1M | |||||
| Net income | -12.2M | -38.8M | -35.2M | -42.7M | -9.41M | 149.8M | -120.2M | -63.8M | -31.4M | -1.60M |
| Earnings per share, basic | -0.04 | -0.12 | -0.12 | -0.14 | -0.04 | 0.51 | -0.41 | -0.26 | -0.13 | -0.03 |
| Earnings per share, diluted | -0.12 | -0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.3M | 115.4M | 162.6M | 205.8M | 215.8M | 183.4M | 89.2M | 3.63M | 3.80M | 2.87M |
| Short-term investments | 0 | 12.2M | 24.9M | 190.3M | 143.6M | 206.4M | ||||
| Receivables | 386.0K | 0 | 3.81M | 25.3M | 19.7M | 8.78K | 8.31M | 6.96M | ||
| Current assets | 61.9M | 117.1M | 165.7M | 211.9M | 255.9M | 229.0M | 291.2M | 152.9M | 214.0M | 24.9M |
| Property, plant and equipment | 5.68M | 3.74M | 4.41M | 9.53M | 9.16M | 408.0K | 173.0K | 110.0K | 89.2K | 9.60K |
| Total assets | 100.0M | 153.5M | 208.2M | 221.5M | 265.6M | 230.0M | 293.1M | 153.3M | 214.5M | 24.9M |
| Accounts payable | 4.07M | 3.68M | 7.06M | 2.31M | 2.75M | 1.61M | 13.4M | 5.52M | 6.08M | |
| Current liabilities | 6.19M | 9.10M | 20.6M | 39.0M | 31.4M | 13.2M | 37.9M | 13.3M | 10.9M | 1.74M |
| Total debt | 3.44M | 5.73M | 5.51M | 7.17M | 284.0K | 790.1K | ||||
| Total liabilities | 8.42M | 17.3M | 36.9M | 64.5M | 71.5M | 51.2M | 50.5M | 13.3M | 10.9M | 1.74M |
| Shareholders' equity | 91.5M | 136.2M | 171.3M | 157.0M | 194.1M | 178.8M | 242.6M | 140.1M | 203.5M | 23.2M |
| Shares outstanding | 326.5M | 323.5M | 300.5M | 301.5M | 264.3M | 292.6M | 292.8M | 242.4M | 241.8M | 55.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.5M | -51.2M | -96.6M | -20.7M | 1.16M | 180.3M | -92.1M | -62.8M | -62.8M | -1.60M |
| Capital spending | -38.0K | -71.0K | -1.90M | -2.67M | -871.0K | -99.0K | -667.2K | -79.0K | -79.0K | -6.43K |
| Free cash flow | -29.5M | -51.3M | -98.5M | -23.4M | 284.0K | 180.2M | -92.7M | -62.9M | -62.9M | -1.61M |
| Cash from investing | 3.52M | 6.93M | 7.04M | 11.1M | 10.8M | -6.02M | -79.5M | -79.0K | -79.0K | 28.9K |
| Cash from financing | -33.6M | -1.40M | 44.6M | 360.0K | 20.4M | -290.0K | 227.1M | 337.0K | 337.0K | 2.35M |
| Dividends paid | -32.3M | |||||||||
| Share buybacks | 0 | 45.7M | 1.80M | 21.2M | 0 | 26.0M | 37.5K | 23.3M | 2.37M | |
| Change in cash | -55.1M | -45.7M | -45.0M | -9.85M | 32.4M | 173.7M | -55.3M | 144.5M | -62.5M | 782.8K |
Cap table
Built by 6ix from Nykode Therapeutics ASA’s releases
- Common shares
- 391,546,444
- Fully diluted
- 391,546,444
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 391,546,444 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 391,546,444 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Agnete B. Fredriksen | Chief Scientific Officer & Business Development · Since at least Aug 20, 2026 |
| Barbara Krebs-Pohl | Chair of the Board · Since at least May 27, 2026 |
| Christian Åbyholm | Board Member · Since at least May 27, 2026 |
| Harald Gurvin | Chief Financial Officer · Since at least May 27, 2026 |
| Jakob Helding Rasmussen | Chief Technology Officer · Since at least Nov 5, 2026 |
| John Beadle | Board Member · Since at least May 27, 2026 |
| Louise Stubbe | Chief Legal Officer · Since at least Nov 5, 2026 |
| Michael Engsig | Chief Executive Officer · Since at least Aug 20, 2026 |
| Susanne Stuffers | Board Member · Since at least May 27, 2026 |
| Trygve Lauvdal | Board Member · Since at least May 27, 2026 |
Log in to ask 6ix AI your own questions about Nykode Therapeutics ASA.